| Lorlatinib studied in …STUDIED_INderived56 of 56show fewer |
|---|
| → studied in | NCT05144997Phase 4 · active not recruiting Lorlatinib Continuation Study · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07617337Phase 1 · recruiting AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer · 56 trials list this drug (28 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07567352active not recruiting A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment · 56 trials list this drug (28 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03126916Phase 3 · recruiting Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) · 56 trials list this drug (28 active) | — | — | Ganglioneuroblastoma,Neuroblastoma,Ganglioneuroblastoma, Nodular | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07784959Phase 1 · recruiting Study of NXP900 With Lorlatinib in ALK+ Lung Cancer · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma,ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06007937Phase 1/Phase 2 · active not recruiting A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07556549active not recruiting A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC · 56 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07750704Phase 2 · not yet recruiting Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC · 56 trials list this drug (28 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06678555completed A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out. · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06333899early Phase 1 · recruiting Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion · 56 trials list this drug (28 active) | — | — | Anaplastic Astrocytoma,Glioblastoma,Diffuse Intrinsic Pontine Glioma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03505554Phase 2 · completed A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma · 56 trials list this drug (28 active) | — | — | Anaplastic Large Cell Lymphoma, ALK-Positive | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04800822Phase 1 · terminated PF-07284892 in Participants With Advanced Solid Tumors · 56 trials list this drug (28 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05297890Phase 2 · active not recruiting A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer · 56 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06487078NA · recruiting Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context · 56 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07415005Phase 2 · recruiting Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03737994Phase 2 · terminated Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer · 56 trials list this drug (28 active) | — | — | Malignant Lung Neoplasm,Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06282874Phase 4 · active not recruiting Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05599412recruiting Post Marketing Surveillance(PMS) Study of Lorviqua in Korea · 56 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06282991completed A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05740943Phase 2 · active not recruiting Induction Lorlatinib in Stage III Non-small Cell Lung Cancer · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03052608Phase 3 · active not recruiting A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03909971Phase 2 · completed A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04621188Phase 2 · active not recruiting Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) · 56 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03107988Phase 1 · completed NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) · 56 trials list this drug (28 active) | — | — | Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07083687Phase 2 · not yet recruiting Lorlatinib in ROS1+ NSCLC With Brain Metastasis · 56 trials list this drug (28 active) | — | — | Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04362072Phase 4 · completed Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer · 56 trials list this drug (28 active) | — | — | Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04111705Phase 2 · completed Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer · 56 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05834348completed A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06893354Phase 4 · not yet recruiting Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06876675enrolling by invitation LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06858410Phase 3 · not yet recruiting Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma · 56 trials list this drug (28 active) | — | — | Lung Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05097599Phase 2 · terminated StrataPATH™ (Precision Indications for Approved Therapies) · 56 trials list this drug (28 active) | — | — | Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04541706Phase 4 · completed Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06690541not yet recruiting Real-world Study of Local Therapy Changes During 1L Lorlatinib in Unresectable ALK+ NSCLC · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06682884Phase 2 · not yet recruiting Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer · 56 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04127110Phase 2 · active not recruiting Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04753658terminated Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib · 56 trials list this drug (28 active) | — | — | Neuroblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01970865Phase 1/Phase 2 · completed A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06532149recruiting ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03546894completed A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03726333Phase 1 · terminated Hepatic Impairment Study for Lorlatinib in Cancer Patients · 56 trials list this drug (28 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06410040unknown A Retrospective Study of the Efficacy and Safety of Lolatinib in ALK+ NSCLC Patients With Brain or Meningeal Metastasis · 56 trials list this drug (28 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06378892Phase 2 · recruiting A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib · 56 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06361589recruiting Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients · 56 trials list this drug (28 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · 56 trials list this drug (28 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02925234Phase 2 · recruiting The Drug Rediscovery Protocol (DRUP Trial) · 56 trials list this drug (28 active) | — | — | Neoplasm,Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05948462Phase 2 · withdrawn Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib · 56 trials list this drug (28 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02584634Phase 1/Phase 2 · terminated Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101) · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04647110completed Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers. · 56 trials list this drug (28 active) | — | — | ALK-Positive Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05167500completed Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03612154Phase 2 · unknown Study of Lorlatinib in ROS1 Rearranged NSCLC · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03439215Phase 2 · unknown PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04292119Phase 1/Phase 2 · unknown Lorlatinib Combinations in Lung Cancer · 56 trials list this drug (28 active) | — | — | Malignant Neoplasm,Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02927340Phase 2 · unknown A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions · 56 trials list this drug (28 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03178071no longer available Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive · 56 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03184168Phase 1 · completed Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers · 56 trials list this drug (28 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |